Please login to the form below
Ganymed Pharmaceuticals
This page shows the latest Ganymed Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Astellas agrees €800m deal to buy Belgian biotech Ogeda
This is the second major deal for Astellas in a few months, following a $1.4bn acquisition of Germany's Ganymed Pharmaceuticals that gave it a gastric cancer antibody (IMAB362) in
Latest news
-
Astellas buys Ganymed to boost immuno-oncology pipeline
Astellas has agreed to pay 422m upfront to buy Ganymed Pharmaceuticals, a German biopharma company specialising in antibody-based cancer drugs. ... If all goes according to plan, Ganymed's shareholders could pick up an additional 860m in milestones,
-
Hexal co-founders continue biotech buy up
The Struengmanns already hold stakes in German biotechnology companies including 4SC and Ganymed Pharmaceuticals, which is developing monoclonal antibody therapeutics to fight solid cancer tumours.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Imperial College London to lead major coronavirus home testing programme
- ViiV takes on Gilead’s PReP dominance with HIV injectable data
- Moderna’s coronavirus vaccine hits first objectives
- Roche says antibody test for COVID-19 should be ready in May
- AZ secures capacity for one billion coronavirus vaccine doses
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
- Roche makes protein degradation play with $135m Vividion deal
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- UK government expands coronavirus testing criteria
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
- OPEN Health use PR to support clinical trial recruitment
- International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...
Quick links
Infographics
